Cardinal Health, Inc. vs Intel Corporation: Strategic Comparison

This in-depth comparison examines Cardinal Health, Inc. and Intel Corporation across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Cardinal Health, Inc. on its own, evaluating Intel Corporation, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Cardinal Health, Inc. and Intel Corporation is widest.

On the headline numbers, Cardinal Health, Inc. reports annual revenue of $254.2B against $52.9B for Intel Corporation, while their respective market capitalizations stand at $56.0B and $639.9B. Both Cardinal Health, Inc. and Intel Corporation are headquartered in United States, so they compete in a shared home market and regulatory environment.

Cardinal Health, Inc.: Cardinal Health, based in Ohio, is one of the three large US pharmaceutical distributors, along with McKesson and Cencora. It does not invent drugs or treat patients. It runs the regulated supply chain that moves medicines and medical devices from manufacturers to pharmacies and hospitals, so a prescription collected at a local pharmacy has often passed through its network.

Intel Corporation: Intel was founded in 1968 by Robert Noyce and Gordon Moore and became the defining PC chip company through the x86 architecture, the 'Intel Inside' brand, and its partnership with Microsoft. It missed the smartphone shift, suffered years of 10nm and 7nm delays, and lost Apple's Mac business to Apple silicon in 2020. Pat Gelsinger's IDM 2.0 plan (2021-2024) rebuilt the process roadmap at high cost. Lip-Bu Tan, CEO since March 2025, has focused on cost cuts, customer focus, and new capital from the U.S. government, Nvidia, and SoftBank.

Cardinal Health, Inc. and Intel Corporation pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Cardinal Health, Inc. and Intel Corporation.

Cardinal Health, Inc. business model: The business model is large, high-volume logistics divided into two segments: Pharmaceutical and Medical. In the Pharma segment, they buy billions of dollars of drugs from manufacturers (like Pfizer) and distribute them daily to tens of thousands of pharmacies and hospitals, taking a tiny markup. In the Medical segment, they actually manufacture and distribute low-cost, high-volume medical supplies (like surgical gloves, gowns, and syringes), acting as the large central supply closet for the entire American hospital system.

Intel Corporation business model: Intel is an integrated device manufacturer (IDM): it designs chips and runs its own fabs in Oregon, Arizona, New Mexico, Ireland, and Israel. Since 2024 it reports two halves. Intel Products (client CPUs, Xeon data-center CPUs, AI accelerators) sells to OEMs, hyperscalers, and enterprises. Intel Foundry manufactures wafers and packages for Intel Products and for external customers, competing with TSMC and Samsung. Intel also owns a majority of Mobileye (ADAS chips) and kept a 49% stake in Altera after selling 51% to Silver Lake in September 2025.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Cardinal Health, Inc. stack up against those of Intel Corporation.

Cardinal Health, Inc. competitive advantage: Cardinal Health's advantage is physical scale and regulatory standing. Moving regulated, temperature-sensitive drugs and biologics across the country overnight takes a network of specialized distribution centers and security procedures that cost billions of dollars and take decades to build. The barrier to entry is high, so drug distribution is concentrated among a few large companies.

Intel Corporation competitive advantage: Intel's advantages are the installed base of x86 software, deep OEM and enterprise relationships, leading-edge U.S. fabs, and advanced packaging (EMIB, Foveros) that AI chip designers increasingly need. Its role as the main American maker of leading-edge logic chips also brings policy support: the U.S. government became its largest shareholder in August 2025.

Future prospects matter as much as current results. The growth strategies below explain how Cardinal Health, Inc. and Intel Corporation each plan to expand from here.

Cardinal Health, Inc. growth strategy: Cardinal Health's growth plan rests on three levers. First, specialty pharmaceuticals and physician practice platforms: it bought a 71% stake in GI Alliance for about $2.8 billion (announced November 2024) and funded The Specialty Alliance's roughly $1.9 billion acquisition of urology MSO Solaris Health (completed November 2025). Second, the Other segment: Nuclear and Precision Health Solutions (radiopharmaceuticals and theranostics), at-Home Solutions (expanded with ADSG in 2025, Strive Medical, and the announced AdaptHealth diabetes business), and OptiFreight Logistics, which together grew revenue 26% to $6.8 billion in fiscal 2026. Third, improving GMPD profitability through its Cardinal Health brand products and cost actions.

Intel Corporation growth strategy: Under Lip-Bu Tan, Intel has cut layers and headcount, slowed some fab projects such as Ohio, and tied foundry spending to committed customer demand. Growth bets for 2026-2027 are Xeon CPUs for AI servers (DCAI revenue rose 59% year over year in Q2 2026), Panther Lake AI PC processors on Intel 18A, advanced packaging for third-party AI chips, custom x86 parts co-developed with Nvidia, and winning external customers for the 14A node.

A closer look at the financial trajectory of Cardinal Health, Inc. and Intel Corporation rounds out the comparison.

Cardinal Health, Inc.: Cardinal Health combines very large revenue with thin margins. Fiscal 2026 revenue was $254.2 billion, up 14% from $222.6 billion in fiscal 2025, driven by brand and specialty drug volume from existing customers. GAAP operating earnings were $2.6 billion, GAAP diluted EPS was $7.23, and net earnings attributable to Cardinal Health were about $1.7 billion. Non-GAAP diluted EPS rose 37% to $11.26 ($10.95 excluding the IEEPA tariff refund). Operating cash flow was $5.2 billion and adjusted free cash flow was $5.0 billion. The company repurchased $1.4 billion of stock in fiscal 2026 and the board added $5.0 billion to the buyback authorization in August 2026. Fourth-quarter fiscal 2026 revenue was $63.7 billion, up 6%.

Intel Corporation: Intel's revenue peaked at $79.0 billion in 2021 and fell to $53.1 billion in 2024, when it posted an $18.8 billion net loss driven by restructuring and impairments. FY2025 revenue was $52.9 billion with a much smaller $267 million net loss, and the year ended with $37.4 billion in cash and short-term investments. Q2 2026 revenue rose 25% to $16.1 billion with a 41.8% non-GAAP gross margin and $0.42 non-GAAP EPS. GAAP net loss for the quarter was $11.0 billion, almost all from a $12.5 billion non-cash mark-to-market charge on shares escrowed for the U.S. Department of Commerce. Intel guided Q3 2026 revenue to $15.8-16.8 billion.